Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 16357179)

1.

Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines.

Lecane PS, Karaman MW, Sirisawad M, Naumovski L, Miller RA, Hacia JG, Magda D.

Cancer Res. 2005 Dec 15;65(24):11676-88.

2.

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

Magda D, Lecane P, Miller RA, Lepp C, Miles D, Mesfin M, Biaglow JE, Ho VV, Chawannakul D, Nagpal S, Karaman MW, Hacia JG.

Cancer Res. 2005 May 1;65(9):3837-45.

3.

Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.

Evens AM, Balasubramanian L, Gordon LI.

Curr Treat Options Oncol. 2005 Jul;6(4):289-96. Review.

PMID:
15967082
5.

Silver ions induce oxidative stress and intracellular zinc release in human skin fibroblasts.

Cortese-Krott MM, Münchow M, Pirev E, Hessner F, Bozkurt A, Uciechowski P, Pallua N, Kröncke KD, Suschek CV.

Free Radic Biol Med. 2009 Dec 1;47(11):1570-7. doi: 10.1016/j.freeradbiomed.2009.08.023. Epub 2009 Sep 3.

PMID:
19733233
6.

Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation.

Ramos J, Sirisawad M, Miller R, Naumovski L.

Mol Cancer Ther. 2006 May;5(5):1176-82.

7.

Metallothionein induction by hypoxia involves cooperative interactions between metal-responsive transcription factor-1 and hypoxia-inducible transcription factor-1alpha.

Murphy BJ, Kimura T, Sato BG, Shi Y, Andrews GK.

Mol Cancer Res. 2008 Mar;6(3):483-90. doi: 10.1158/1541-7786.MCR-07-0341.

8.

Motexafin gadolinium: a novel redox active drug for cancer therapy.

Magda D, Miller RA.

Semin Cancer Biol. 2006 Dec;16(6):466-76. Epub 2006 Sep 26. Review.

PMID:
17112739
9.

Zinc-sensitive genes as potential new target genes of the metal transcription factor-1 (MTF-1).

Kindermann B, Döring F, Budczies J, Daniel H.

Biochem Cell Biol. 2005 Apr;83(2):221-9.

PMID:
15864330
10.

Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.

Singh AT, Evens AM, Prachand SN, Gordon LI.

Anticancer Res. 2010 Apr;30(4):1131-6.

PMID:
20530418
11.

Transcriptome response to heavy metal stress in Drosophila reveals a new zinc transporter that confers resistance to zinc.

Yepiskoposyan H, Egli D, Fergestad T, Selvaraj A, Treiber C, Multhaup G, Georgiev O, Schaffner W.

Nucleic Acids Res. 2006;34(17):4866-77. Epub 2006 Sep 14.

12.
13.

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells.

Evens AM, Lecane P, Magda D, Prachand S, Singhal S, Nelson J, Miller RA, Gartenhaus RB, Gordon LI.

Blood. 2005 Feb 1;105(3):1265-73. Epub 2004 Sep 23.

14.

Understanding the mechanisms of zinc-sensing by metal-response element binding transcription factor-1 (MTF-1).

Laity JH, Andrews GK.

Arch Biochem Biophys. 2007 Jul 15;463(2):201-10. Epub 2007 Apr 4. Review.

PMID:
17462582
15.
16.
17.

Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).

Zahedi Avval F, Berndt C, Pramanik A, Holmgren A.

Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9. doi: 10.1016/j.bbrc.2008.12.128. Epub 2009 Jan 1.

PMID:
19121624
18.

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.

Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A.

J Biol Chem. 2006 Apr 21;281(16):10691-7. Epub 2006 Feb 14.

19.

Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.

Sieber S, Gdynia G, Roth W, Bonavida B, Efferth T.

Int J Oncol. 2009 Jul;35(1):149-58.

PMID:
19513562
20.

Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities.

Evans JP, Xu F, Sirisawad M, Miller R, Naumovski L, de Montellano PR.

Mol Pharmacol. 2007 Jan;71(1):193-200. Epub 2006 Oct 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk